



Guest Editors

David J. Jackson



David J. Jackson is an Associate Professor of Respiratory Medicine at King's College London (London, UK) and Clinical Director of Guy's Severe Asthma Centre, Guy's & St Thomas' NHS Trust (London, UK), a regional unit for severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA) and other eosinophilic lung diseases, which receives approximately 1000 referrals per year from a network of hospitals across London and South-East England.

Following an MSc in allergy and a PhD investigating the mechanisms of virus-induced asthma exacerbations at Imperial College London (London, UK), David's more recent research has focused on the clinical aspects of severe asthma care, including investigating subphenotypes of asthma and EGPA made evident by their differential response to targeted biological therapies.

David is on the steering committee of the International Severe Asthma Registry (ISAR), is an assembly member of the Global Initiative for Asthma (GINA), and is on the asthma specialist advisory group of the British Thoracic Society (BTS). He holds senior editorial positions at several journals, including *Chest*, the *European Respiratory Review* and *Allergy*, and has published original research in *Nature Medicine*, *Science Translational Medicine*, *JAMA Internal Medicine* and *Lancet Respiratory Medicine*, as well as several other respiratory- and allergy-related journals.

Michael E. Wechsler



Michael E. Wechsler is Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at National Jewish Health (NJH) in Denver (CO, USA), Director of the NJH/Cohen Family Asthma Institute (Denver) and Associate Vice President for Innovation and Industry Relations at NJH.

Michael received AB and MMSc degrees from Harvard University (Boston, MA, USA) and an MD degree from McGill University (Montreal, QC, Canada). He completed medical training at Beth Israel Hospital (Boston), and as part of the Harvard Combined Pulmonary and Critical Care Fellowship Training Program.

In addition to clinical work in pulmonary and critical care medicine, Michael's research focuses on clinical and translational asthma, with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics and management of eosinophilic granulomatosis with polyangiitis (EGPA). He has led studies focusing on novel biological agents for asthma and related diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, and tezepelumab.

Michael was a member of the Steering Committee and site Principal Investigator for the National Institutes of Health (NIH)-sponsored Asthma Clinical Research Network (ACRN; now called AsthmaNet), a multicentre asthma clinical trials consortium. He currently serves as the Principle Investigator of the Denver site of the Precision Intervention in Severe/Exacerbating Asthma (PRECISE) network.

A member of the American Society of Clinical Investigation, Michael has participated in many different task forces related to the study of eosinophilic lung diseases, sponsored by the NIH, the Food and Drug Administration (FDA), the European Respiratory Society (ERS) and the International Eosinophil Society (IES).

Michael is currently an Associate Editor of *Chest*. He has also served as Associate Editor of *Allergy* as well as on the editorial board of the *European Journal of Clinical Investigation*. Michael has published more than 250 peer-reviewed manuscripts relating to asthma, EGPA and eosinophilic lung diseases.
